TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03991117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: unilateral knee extensions until fatigue with varying load and speeds of contraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: unilateral knee extensions until fatigue with varying load and speeds of contraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: unilateral knee extensions until fatigue with varying load and speeds of contraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: unilateral knee extensions until fatigue with varying load and speeds of contraction
Study: NCT02246335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented total hip arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented hemiarthroplasty
Study: NCT04806594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papix acne scar
Description: PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
Study: NCT02037438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONV care for the diagnosis and treatment of sleep disorders
Description: The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCCM for the diagnosis and treatment of sleep disorders
Description: The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
Study: NCT02255032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA
Description: 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 mg CLS-TA
Description: 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Study: NCT03871088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 12-week double-blind, randomized controlled trial

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 12-week double-blind, randomized controlled trial

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 12-week double-blind, randomized controlled trial
Study: NCT02149446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis (C-SLRA-ECH60) made by COOK Medical
Description: Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
Study: NCT03601312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OC-Go
Description: OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
Study: NCT04038346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Patients will be randomized to an NSAID (naproxen)
Study: NCT03220295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of VU319
Description: Single dose of VU319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of VU319
Description: Single dose of VU319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Dose Placebo
Description: Single dose of placebo
Study: NCT04038346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Patients will be randomized to an NSAID (naproxen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients will be randomized to acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will be randomized to acetaminophen
Study: NCT03051997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Contingency Management + Usual Drug Court Treatment
Description: In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Drug Court Treatment
Description: Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
Study: NCT01650493

Intervention type: DEVICE
Intervention: Clinpro 5000
Description: Dentrifice containing 950ppm fluoride
Study: NCT03220295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Dose Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fed State
Description: drug is given 30 minutes after a high fat breakfast
Study: NCT01650493

Intervention type: DEVICE
Intervention: MI Paste Plus
Description: Dentrifice containing 950ppm fluoride

Intervention type: DEVICE
Intervention: Tom's of Maine
Description: Dentrifice that is fluoride free
Study: NCT03220295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed State
Description: drug is given 30 minutes after a high fat breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fasted State
Description: drug is given after an overnight fast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted State
Description: drug is given after an overnight fast
Study: NCT03484078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Platform
Description: The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Platform
Description: The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
Study: NCT03535350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2.
Study: NCT03220295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise
Study: NCT03535350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy x 30minutes for 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy x 30minutes for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
Study: NCT03224013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
Study: NCT03220295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise
Study: NCT02386657

Intervention type: OTHER
Intervention: Satisfaction
Description: Satisfaction questionnaire to be filled in

Intervention type: OTHER
Intervention: Biological parameters
Description: Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
Study: NCT03220295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise
Study: NCT02386657

Intervention type: OTHER
Intervention: Pain management
Description: Validated pain scale questionnaire to be filled in
Study: NCT02124343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Exercise
Study: NCT03879408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 440 mg naproxen sodium with 1000 mg acetaminophen
Description: 440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 220 mg naproxen sodium with 650 mg acetaminophen
Description: 220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg hydrocodone + 650 mg acetaminophen
Description: 10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 440 mg naproxen sodium
Description: 440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Single dose of four placebo tablets
Study: NCT03220295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose Escalation
Description: dose levels of the cohorts will be increased step wise
Study: NCT03072589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson infusion
Description: Dose escalation of Regadenoson when given as an infusion
Study: NCT02714595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
Study: NCT03958838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Integrated with Primary Care
Description: Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
Study: NCT00671528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
Description: Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream (betamethasone diproprionate and gentamicin)
Description: Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream (betamethasone diproprionate)
Description: Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Study: NCT04468269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented balance training with sensory integration group
Description: Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented balance training without sensory integration group
Description: Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk
Study: NCT03088709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV medication given for prevention of graft versus host disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV medication given for prevention of graft versus host disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: IV medication given for prevention of graft versus host disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haploidentical Stem Cell Transplantation
Description: A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
Study: NCT02913664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
Description: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
Description: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will follow their regular doctor's recommendations for blood pressure and lipid control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
Study: NCT01906307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501
Description: Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
Study: NCT02511067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab (0.3mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab (0.3mg)
Study: NCT02913664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Exercise
Description: Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
Study: NCT04181762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: STUDY DRUG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo